LEADER 01534nam 2200421 450 001 9910698376603321 005 20221024222836.0 035 $a(CKB)3450000000002512 035 $a(NjHacI)993450000000002512 035 $a(OCoLC)168035840 035 $a(EXLCZ)993450000000002512 100 $a20221024d2009 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAspirin for the primary prevention of cardiovascular events $ean update of the evidence for the U.S. preventive services task force /$fTracy Wolff, Therese Miller, Stephen Ko 210 1$aRockville (MD) :$cAgency for Healthcare Research and Quality (US),$d[2009] 210 4$dİ2009 215 $a1 online resource (254 pages) $cillustrations 300 $aTitle from title screen (viewed on Sept. 6, 2007). 300 $a"January 2002." 320 $aIncludes bibliographical references. 517 $aAspirin for the Primary Prevention of Cardiovascular Events 606 $aCardiovascular system$xDiseases 615 0$aCardiovascular system$xDiseases. 676 $a616.1 700 $aWolff$b Tracy A.$01351961 702 $aMiller$b Therese 702 $aKo$b Stephen 712 02$aUnited States.$bAgency for Healthcare Research and Quality. 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910698376603321 996 $aAspirin for the primary prevention of cardiovascular events$93143886 997 $aUNINA